Targeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study

about

Targeted Screening for Latent TB Infection prior to Biologic Therapy to Improve Patient Safety and Reduce Costs: A Prospective Observational Study

Item

http://www.wikidata.org/entity/Q59047425

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2014

@uk

name

Targeted Screening for Latent ...... rospective Observational Study

@en

Targeted Screening for Latent ...... rospective Observational Study

@nl

type

Item

label

Targeted Screening for Latent ...... rospective Observational Study

@en

Targeted Screening for Latent ...... rospective Observational Study

@nl

prefLabel

Targeted Screening for Latent ...... rospective Observational Study

@en

Targeted Screening for Latent ...... rospective Observational Study

@nl

P1476

Targeted Screening for Latent ...... rospective Observational Study

@en

P2093

J. France

http://www.w3.org/2001/XMLSchema#string

R. Hassanzadeh

http://www.w3.org/2001/XMLSchema#string

S. Bawa

http://www.w3.org/2001/XMLSchema#string

P2860

Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs

Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary tuberculosis patients from rural Cambodia.

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry.

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).

Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks.

Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.

P304

1-6

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2014/378908

http://www.w3.org/2001/XMLSchema#string

P478

2014

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime